V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Bio-Techne Corporation Executive Compensation (FY25)

TECH · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): November 5, 2025
374 figures on this page: 364 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Kim Kelderman was paid $8,151,181 in total compensation as President and Chief Executive Officer for fiscal 2025, and the company reported a chief executive pay ratio of 88.9:1 for fiscal 2025, against median employee compensation of $91,707. Separately, shareholders supported the say-on-pay proposal with 71.6% of votes cast including abstentions in favor at the meeting held October 30, 2025 for fiscal 2025, and companies named in the disclosed peer group include Align Technology, Inc., Alkermes plc, Avantor, Inc., Bio-Rad Laboratories, Inc. and EXACT Sciences Corporation, among others. The fiscal 2025 disclosure covers 5 named executive officers.
Chief executive, fiscal 2025
◇
Kim Kelderman
Latest say-on-pay support
=
October 30, 2025
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2023 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Chuck Kummeth → Kim Kelderman
Say-on-pay support: 86.0% → 71.6% (14.4 points lower)
CEO pay ratio: 78.5:1 → 88.9:1 (13.2% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bio-Techne Corporation's chief executive and what were they paid?
Kim Kelderman was paid $8,151,181 in total compensation as President and Chief Executive Officer for fiscal 2025.
What was Bio-Techne Corporation's say-on-pay result?
Shareholders supported the say-on-pay proposal with 71.6% of votes cast including abstentions in favor at the meeting held October 30, 2025 for fiscal 2025.
Which companies are in Bio-Techne Corporation's peer group?
Companies named in the disclosed peer group include Align Technology, Inc., Alkermes plc, Avantor, Inc., Bio-Rad Laboratories, Inc. and EXACT Sciences Corporation, among others.
What is Bio-Techne Corporation's chief executive pay ratio?
The company reported a chief executive pay ratio of 88.9:1 for fiscal 2025, against median employee compensation of $91,707.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chuck Kummeth
Former Chief Executive Officer
◇—◇◇◇—◇◇
James Hippel
Executive Vice President – Finance and Chief Financial Officer
◇—◇◇◇—◇◇
William Geist
President – Protein Sciences
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chuck Kummeth
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
James Hippel
Executive Vice President – Finance and Chief Financial Officer
◇—◇◇◇—◇◇
William Geist
President – Protein Sciences
◇—◇◇——◇◇
Shane Bohnen
Senior Vice President – General Counsel and Corporate Secretary
◇—◇◇◇——◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kim Kelderman
President and Chief Executive Officer
◇—◇◇◇—◇◇
James Hippel
Executive Vice President Finance and Chief Financial Officer
◇—◇◇◇—◇◇
William Geist
President Protein Sciences
◇—◇◇◇—◇◇
Matthew McManus
President Diagnostics and Spatial Biology
◇—◇◇◇—◇◇
Shane Bohnen
Senior Vice President General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James HippelRSU◇——◇——◇
James HippelOPTION◇——◇—◇◇
James HippelRSU◇——◇——◇
James HippelPSU◇◇◇◇◇—◇
Kim KeldermanPSU◇◇◇◇◇—◇
Kim KeldermanOPTION◇——◇—◇◇
Kim KeldermanRSU◇——◇——◇
Matthew McManusOPTION◇——◇—◇◇
Matthew McManusRSU◇——◇——◇
Matthew McManusPSU◇◇◇◇◇—◇
Shane BohnenPSU◇◇◇◇◇—◇
Shane BohnenRSU◇——◇——◇
Shane BohnenOPTION◇——◇—◇◇
William GeistOPTION◇——◇—◇◇
William GeistRSU◇——◇——◇
William GeistPSU◇◇◇◇◇—◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James HippelOption◇—◇8/5/2027
Option◇—◇8/15/2030
RSU◇◇——
Option◇—◇8/6/2028
Option◇—◇8/5/2027
Option◇—◇8/8/2025
RSU◇◇——
Option◇—◇8/8/2025
Option◇—◇8/15/2029
Option◇—◇8/5/2027
Option◇—◇8/7/2026
Option◇—◇8/15/2029
Option◇—◇8/15/2030
Option◇—◇8/7/2026
Option◇—◇8/15/2034
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Kim KeldermanOption◇—◇8/15/2029
RSU◇◇——
Option◇—◇8/15/2030
Option◇—◇8/5/2027
Option◇—◇8/8/2025
Option◇—◇8/5/2027
Option◇—◇2/1/2031
Option◇—◇8/15/2030
Option◇—◇8/8/2025
PSU◇◇——
Option◇—◇8/7/2026
Option◇—◇8/6/2028
PSU◇◇——
Option◇—◇2/1/2031
RSU◇◇——
Option◇—◇8/7/2026
PSU◇◇——
PSU◇◇——
Option◇—◇8/15/2034
Option◇—◇8/5/2027
Option◇—◇8/15/2029
Shane BohnenOption◇—◇4/3/2030
Option◇—◇8/15/2029
Option◇—◇8/5/2027
Option◇—◇8/6/2028
PSU◇◇——
Option◇—◇8/7/2026
Option◇—◇8/15/2030
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇8/15/2030
Option◇—◇8/15/2034
Matthew McManusRSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇2/1/2031
RSU◇◇——
Option◇—◇8/15/2034
Option◇—◇2/1/2031
William GeistOption◇—◇8/15/2029
Option◇—◇2/1/2029
RSU◇◇——
PSU◇◇——
Option◇—◇8/15/2030
Option◇—◇8/15/2029
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇8/15/2030
Option◇—◇8/15/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert V. Baumgartner
Board chair
◇◇◇——◇◇
John L. Higgins
◇◇◇——◇◇
Julie L. Bushman
◇◇◇——◇◇
Roeland Nusse, Ph.D
◇◇◇——◇◇
Alpna Seth, Ph.D
◇◇◇——◇◇
Joseph Keegan, Ph.D
◇◇◇——◇◇
Rupert Vessey, MA, BM BCh, FRCP, DPhil
◇◇◇——◇◇
Judith Klimovsky, M.D
◇◇◇——◇◇
Amy Herr, Ph.D
◇◇◇——◇◇
Randolph C Steer, M.D., Ph.D
◇————◇◇
Kim Kelderman served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Equity is delivered as 50% Stock Options, 50% Restricted Stock.
Stock ownership guideline: 3x annual retainer ($225,000)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Align Technology, Inc. ALGN
  • Alkermes plc ALKS
  • Avantor, Inc. AVTR
  • Bio-Rad Laboratories, Inc. BIO
  • EXACT Sciences Corporation EXAS
  • Globus Medical, Inc. GMED
  • Haemonetics Corporation HAE
  • Insulet Corporation PODD
  • Integra LifeSciences Holdings Corp IART
  • Masimo Corporation MASI
  • Natera, Inc. NTRA
  • Penumbra, Inc. PEN
  • QIAGEN N.V. QGEN
  • QuidelOrtho Corporation QDEL
  • Repligen Corporation RGEN
  • Revvity Inc. RVTY
  • Teleflex Inc. TFX
  • Waters Corp. WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025October 30, 2025=◇◇◇
2024October 25, 2024=◇◇◇
2023October 26, 2023=◇◇◇
2022October 27, 2022=◇◇◇
2021October 28, 2021=◇◇◇
2020November 2, 2020=◇◇◇
2019October 28, 2019=◇◇◇
2018October 26, 2018=◇◇◇
2017October 26, 2017=◇◇◇
2016October 28, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Bio-Techne Corporation files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bio-Techne Corporation disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bio-Techne Corporation sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Bio-Techne Corporation's disclosed peer group is defensible, who names Bio-Techne Corporation back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
374 figures on this page: 364 cited to the filing that reported them, 10 calculated from figures it prints.
364 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001104659-25-106631
  2. 0001308179-25-000599
    2024 Outstanding Equity Awards at Fiscal Year-End · 2025 Summary Compensation Table · Compensation Paid to the Non-Employee Directors · Director Compensation · and 2 more sections
  3. 0001558370-24-013879
  4. 0001558370-23-017051
  5. 0001308179-23-000977
    2023 Summary Compensation Table · Summary Compensation Table
  6. 0001558370-22-015710
  7. 0001437749-21-024664
  8. 0001437749-20-022390
  9. 0001437749-19-020780
  10. 0001437749-18-018887
  11. 0001437749-17-017673
  12. 0001437749-16-040643
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bio-Techne Corporation executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TECH (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bio-Techne Corporation and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bio-Techne Corporation discloses

The companies named in TECH's own disclosed peer group.

Align Technology, Inc.Alkermes plcAvantor, Inc.Bio-Rad Laboratories, Inc.Globus Medical, Inc.Haemonetics CorporationInsulet CorporationIntegra LifeSciences Holdings CorpMasimo CorporationPenumbra, Inc.Repligen CorporationRevvity Inc.Teleflex Inc.Waters Corp.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy